Skip to content

Study · Non-randomized trial · n = 68 · 1995

3 results

Treatment with thymosin alpha-1 increases fertilizing capacity of sperm of infertile men: a multicenter trial.

Naz RK, Menge AC, Sacco A

Archives of andrology1 Sept 1995Cited by 1 (Europe PMC)

PMID8579476 (opens in a new tab)DOI10.3109/01485019508987866 (opens in a new tab)PepBankPUB-08579476
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In infertile men, thymosin alpha‑1 increased sperm fertilizing capacity by 31 to 45% (p = .0006 to < .0001) in the 76% (50/68) of men whose sperm responded in the sperm penetration assay.

    In plain wordsIn infertile men, thymosin alpha‑1 raised the fertilizing ability of sperm in a lab sperm penetration test.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseFertilizing capacity of sperm (sperm penetration index)
    Study

    n = 68

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Increase in fertilizing capacity
    31 to 45%
    sperm penetration index in SPA

    Source sentences

    Summary
    T alpha 1 significantly (p = .0006 to < .0001) increased (31 to 45%) fertilizing capacity of sperm of 76% (50/68) of infertile men as defined by the sperm penetration index in SPA.
    1 context sentence
    Summary · context
    The present study was conducted to investigate the effect of T alpha 1 on fertilizing capacity of sperm of infertile men using the sperm penetration assay (SPA) in a multicenter clinical trial.
  2. 02HumanNon-randomized trialEfficacy outcome

    In infertile men, thymosin alpha‑1 increased sperm fertilizing capacity in 76% (50/68) of the men.

    In plain wordsIn infertile men, thymosin alpha‑1 raised sperm fertilizing ability in about three of four men tested.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseProportion of infertile men with increased fertilizing capacity
    Study

    n = 68

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Responders
    76%
    infertile men

    Source sentences

    Summary
    T alpha 1 significantly (p = .0006 to < .0001) increased (31 to 45%) fertilizing capacity of sperm of 76% (50/68) of infertile men as defined by the sperm penetration index in SPA.
    1 context sentence
    Summary · context
    The present study was conducted to investigate the effect of T alpha 1 on fertilizing capacity of sperm of infertile men using the sperm penetration assay (SPA) in a multicenter clinical trial.
  3. 03HumanNon-randomized trialMechanism

    In infertile men, the enhancing effect of thymosin alpha‑1 on sperm fertilizing capacity correlated significantly with its concentration in seminal plasma.

    In plain wordsIn infertile men, the sperm benefit of thymosin alpha‑1 was linked to its concentration in seminal fluid.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableCorrelation of enhancement with seminal plasma T alpha 1 concentration
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The enhancing effect of T alpha 1 and the degree of enhancement depended on the T alpha 1 concentration in the seminal plasma, since these parameters showed a significant intercorrelation (r = .65 to .74, p = .039 to .01).
    1 context sentence
    Summary · context
    The present study was conducted to investigate the effect of T alpha 1 on fertilizing capacity of sperm of infertile men using the sperm penetration assay (SPA) in a multicenter clinical trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.